Page 2 - Dr Lal Pathlabs

Dr Lal PathLabs Q4 results: Net profit jumps 49% to Rs 84.5 crore

Eyes expansion into Tier 3 and Tier 4 towns

Dr. Lal PathLabs Q4 results: Net profit rises 49% on healthy testing demand

The company's consolidated net profit jumped 49% year-on-year to Rs 84.5 crore ($10.1 million) in the fourth quarter

Preventive and wellness tests drive growth for diagnostic companies

Covid-19 led to increase in self-testing awareness, particularly about preventive and wellness services

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%

Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%

Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities

Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%

The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu

As Covid-19 cases rise in India; should you keep pharma stocks on radar?

Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.

Major fire in pathology lab building in Delhi's Rohini; nobody injured

A major fire broke out in a pathology laboratory in north Delhi's Rohini late last night, the fire department said on Monday. No one was reported injured. Officials said that the fire broke out on the third and fourth floor of a building which housed the pathology lab. The fire was reported to the department around 12.45 am. "Total 10 fire engines were rushed to the spot immediately. It took more than two hours to douse the flames completely. The fire was near the lift shaft. No one was injured in the fire," an official of the Delhi Fire Service said. The person said that the police have been informed for further investigation into the matter.

Dr Lal PathLabs Q2 results: Profit jumps 54.8%, revenue rises 12.63%

Dr Lal PathLab's share price rose to 3.30 per cent, ending the day's trade at Rs 2,455 apiece on the BSE

Dr Lal Pathlabs Q1FY24 result: Profit up 17% YoY; Rs 6 dividend declared

The total income for Q1FY24 came in at Rs 495.1 crore, compared to Rs 459.3 crore year-on-year

Dr Lal PathLabs reports decline in profit for quarter ending March

Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from Covid-related testing outpaced growth in its core business

No rerating yet for diagnostic players despite price hikes as margins fall

While discounts have come down, pricing gap still large between incumbents and new players

No rerating yet for diagnostic players despite price hikes as margins fall

While discounts have come down, pricing gap still large between incumbents and new players

Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr

Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter. The company had reported a net profit of Rs 58 crore in the October-December quarter of the previous fiscal. Revenue also declined to Rs 489 crore for the period under review as compared with Rs 497 crore in the year-ago period, the company said in a regulatory filing. "We continue to focus on geographical expansion and strengthen our presence in Tier 2, Tier 3 towns. Our focus continues to take a higher market share in West and South markets by leveraging technology and promoting high-end super specialty test portfolios," Dr Lal PathLabs Managing Director Om Manchanda said. Shares of the company were trading 1.63 per cent down at Rs 2,019.15 apiece on the BSE.

Pharma, healthcare Q3FY23 preview: Cost pressures abating to aid margins

Hospitals are expected to report a soft Q3 result due to a mix of seasonality and easing pent-up demand, however, average revenue per occupied bed is likely to remain steady

Lal PathLabs targets leadership position in west India in 5 years

Om Manchanda, MD, Dr Lal Pathlabs said that the contribution of the west zone has gone up from 6 percent in FY15 to 8 percent in FY20 and 15 percent in the first half of FY23

Healthcare stocks rally up to 8% as Covid cases spurt in China, Japan

Reports suggest that Union Health Minister Mansukh Mandaviya will review the Covid-19 pandemic situation, in view of a spurt in COVID-19 cases in Japan, South Korea, Brazil, China and the US.

Multiple headwinds could act as margin tourniquet for diagnostics

Competitive pressures, valuations cap gains from current levels

Dr Lal PathLabs Q2 profit slumps on falling Covid income, higher expenses

Indian medical diagnostics firm Dr. Lal PathLabs Ltd on reported a 24.5% drop in September quarter profit as a sustained decline in revenue and volume from its Covid-19 related business

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics